In Celexir’s organ-support lineup, Cardiogen is positioned for patients who need targeted cardiac recovery—aging adults, those recovering from ischemia, or individuals with elevated cardiometabolic risk. The clinical intent is to maintain cardiovascular performance while supporting tissue-level repair and resilience under stress.
Mechanistically, Cardiogen regulates protein synthesis in cardiomyocytes, improves cardiac metabolism, and promotes structural regeneration. It also enhances microvascular circulation, supporting myocardial perfusion and durability during recovery and high-load states—key levers for functional heart health in longevity care.
Clinical use is as an adjunct inside comprehensive cardiovascular programs—paired with blood pressure, lipid, glucose, sleep/circadian, and exercise interventions—to translate cellular support into measurable outcomes. Within Celexir’s Organ Specific Support framework, Cardiogen is engineered for regenerative precision in systems most vulnerable to age and chronic stress. Track benefit with objective markers (symptoms, recovery metrics, exercise tolerance) while individualizing cycles to patient context.
Celexir delivery & specs: customizable 5–10 day protocols, >98% purity, 2–8 °C storage, and full CoA per batch. Formulation options include a prefilled injectable pen or freeze-dried vial, designed to keep workflows clean and dosing consistent from warehouse to administration.